



VAMIS SYRUP OF HEAMOGBLBIN (Heamoglobin,+Vit B₁₂+Liver Extract)

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

1. NAME OF THE MEDICINAL PRODUCT

VAMIS SYRUP OF HEAMOGBLOBIN

Hematinic Syrup of Hemoglobin, Liver Extract and Vitamin B₁₂

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 15 ml (one tablespoonful) contains:

Heamogblbin B.P. 16.0% w/v

Vitamin B₁₂ B.P. ... 10 mcg

3. PHARMACEUTICAL FORM

Oral Liquid

A reddish brown syrup with characteristic odour in an amber bottle.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

VAMIS SYRUP OF HEAMOGBLOBIN is indicated for

Iron deficiency anaemia due to chronic blood loss, hook-worm infestation, inadequate intake of iron, etc.

Dimorphic anaemia due to deficiency of Iron, Folic Acid and /or Vitamin B₁₂ (Cyanocobalamin).

Anemia of pregnancy and lactation.



VAMIS SYRUP OF HEAMOGBLBIN (Heamoglobin,+Vit B₁₂+Liver Extract)

Tonic in general weakness, lack of appetite, rundown conditions and convalescence.
Post surgery and other debilitated states.

4.2 Posology and method of administration

For Adults: (For Therapeutic use) 1 tablespoonful (15ml) twice a day after meals.

For Children: As advised by the Physician.

Method of administration

Oral

4.3 Contraindications

Primary (idiopathic) or secondary iron storage disease.

Anaemia associated with ineffective erythropoiesis, marrow hypoplasia, sideroblastic change, uncomplicated Cyanocobalamin or folate deficiency.

Intestinal disease (oral iron may aggravate severe acute inflammatory intestinal disease and is ineffective in patients with extensive small intestinal disease eg. celiac sprue.)

Previous hypersensitivity to any of the ingredient in the syrup.

Known idiosyncrasy to commonly used excipients.

Porphyria cutanea tarda.

Uncontrolled parathyroid disease, sickle cell patients.

4.4 Special warnings and precautions for use

Iron compounds should not be given to patients receiving repeated blood transfusions or to patients with anemia not produced by iron deficiency unless iron deficiency is also present.

Care should be taken in patients with iron storage or iron absorption diseases such as haemochromatosis, hemoglobinopathies or existing gastro-intestinal diseases such as inflammatory bowel disease, intestinal strictures and diverticulae.

Liquid preparations of iron salts should be swallowed through a straw to prevent discoloration of the teeth.



VAMIS SYRUP OF HEAMOGBLBIN (Heamoglobin,+Vit B₁₂+Liver Extract)

4.5 Interaction with other medicinal products and other forms of interaction

Compounds containing Calcium and Magnesium including antacids and mineral supplements and bicarbonates, carbonates, oxalates or phosphates, may also impair the absorption of iron by the formation of insoluble complexes.

Similarly absorption of both iron & tetracyclines is diminished when they are taken concomitantly by mouth. If treatment with both drugs is required, a time interval of about 2 to 3 hours should be allowed between them.

Avoid milk and dairy products at least for 2 hours.

Some agents such as Ascorbic Acid & Citric Acid may actually increase the absorption of iron.

The response to iron may be delayed in patients receiving concomitant parenteral chloramphenicol therapy.

Iron salts can decrease the absorption of bisphosphonates, fluoroquinolones, levodopa, methyldopa, penicillamine and tetracycline.

Iron salts may reduce the efficacy of thyroxine.

4.6 Pregnancy and Lactation

Can be used in Iron deficiency anaemia during Pregnancy and Lactation after considering risk benefit ratio.

4.7 Effects on ability to drive and use machines

Vamis Heamoglobin syrup has no influence on the ability to drive or use machines.

4.8 Undesirable effects

Heamoglobin:

In high or toxic doses or poisoning - Gastrointestinal irritation, abdominal pain with nausea, vomiting and either diarrhoea or constipation. Cardiovascular disorders such as hypotension, tachycardia, metabolic changes including acidosis and hypoglycemia. CNS depression ranging from lethargy to coma..

Cyanacobalamin

No known side effects even with very large doses



VAMIS SYRUP OF HEAMOGBLBIN (Heamoglobin,+Vit B₁₂+Liver Extract)

4.9 **Overdose**

The most sign & Symptoms of overdosage are Gastrointestinal irritation, abdominal pain with nausea, vomiting and either diarrhoea or constipation. Cardiovascular disorders such as hypotension, tachycardia, metabolic changes including acidosis and hypoglycemia. CNS depression ranging from lethargy to coma.

Vomiting is induced immediately followed by parenteral injection of desferroxamine mesylate and then gastric lavage. In the meantime give milk and/or 5% sodium bicarbonate solution by mouth. Fluid replacement is essential. Other measures include symptomatic management and therapy of metabolic and cardiovascular disorders.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamics properties**

Pharmacotherapeutics group: Hematinic syrup,
ATC code: B03AE01

Heamoglobin:

Heamoglobin is one of the best-tolerated iron supplements. It rapidly supplements elemental iron so that iron deficiency is quickly controlled, thus leading to faster correction of anaemia and replenishment of tissue iron stores.

Each tablespoonful of **Vamis Heamoglobin Syrup** provides 160mg of elemental iron. Thus, when an adult takes the recommended dosage of 1 tablespoonful twice a day, he gets 65.6 mg of elemental iron which is sufficient amount of elemental iron per day for an adult patient suffering from mild to moderate iron deficiency.

Cyanocobalamin:

Cyanocobalamin (Vitamin B₁₂) is a complex organo-metallic compound in which a cobalt atom is placed within a corrin ring. It plays an important role in synthesis of DNA and maturation of red cells. It acts as a co-enzyme in certain steps necessary for genetic replication.



5.2 **Pharmacokinetic properties**

Heamoglobin):

Iron irregularly and incompletely absorbed from the gastrointestinal tract, the main sites of absorption being the duodenum and jejunum. Absorption is aided by the acid section of the stomach and by some dietary acids (such as ascorbic acid) and is more readily affected when the iron is in the ferrous state or is part of the haem complex (haem-iron). Absorption is also increased in conditions of iron deficiency or in the fasting state but is decreased if the body stores are overloaded. Only about 5 to 15% of the iron ingested in food is normally absorbed.

Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin.

Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.

Cyanocobalamin bind to intrinsic factor, a glycoprotein secreted by the gastric mucosa, and are then actively absorbed from the gastro-intestinal tract. Absorption is impaired in patients with an absence of intrinsic factor, with a malabsorption syndrome or with disease or abnormality of the gut, or after gastrectomy. Absorption from the gastro-intestinal tract can also occur by passive diffusion.

Cyanocobalamin is extensively bound to specific plasma proteins called transcobalamins; transcobalamin II appears to be involved in the rapid transport of the cobalamins to tissues. Cyanocobalamin is stored in the liver, excreted in the bile and undergoes extensive enterohepatic recycling; part of an administered dose is excreted in the urine, most of it in the first 8 hours; urinary excretion, however, accounts for only a small fraction in the reduction of total body stores acquired by dietary means. Cyanocobalamin diffuses across the placenta and also appears in breast milk.

5.3 **Preclinical safety data**

Toxicology

Iron:

Iron is a general cellular poison and is directly corrosive to the GI mucosa.

Cellular toxicity

The absorption of excessive quantities of ingested iron results in systemic iron toxicity. Severe overdose causes impaired oxidative phosphorylation and mitochondrial dysfunction, which can result in cellular death. The liver is one of the organs most affected by iron toxicity, but other organs such as the heart, kidneys, lungs, and the hematologic systems also may be impaired.

MILD TO MODERATE POISONING: Vomiting and diarrhea may occur within 6 hours of ingestion.



VAMIS SYRUP OF HEAMOGBLBIN (Heamoglobin,+Vit B₁₂+Liver Extract)

SEVERE POISONING: Severe vomiting and diarrhea, lethargy, metabolic acidosis, shock, GI hemorrhage, coma, seizures, hepatotoxicity, and late onset GI strictures.

Vitamin B₁₂:

Vitamin B12 is usually considered a non-toxic substance. Even taking it by injection at high doses does not seem to increase the risk for toxicity.

6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

Liver extract, Carmozine, Methylparaben, Propylparaben, Orange tincture, Granulated sugar, Glycerine.

6.2 **Incompatibilities**

Not applicable.

6.3 **Shelf life**

24 months

6.4 **Special precautions for storage**

Store below 30°C.



VAMIS SYRUP OF HEAMOGBLBIN (Heamoglobin,+Vit B₁₂+Liver Extract)

6.5 Nature and contents of container <and special equipment for use, administration or implantation>

Primary packaging materials: 200ml amber coloured rectangular glass bottles with 28mm PP caps.

Secondary packaging material: Mono-carton

6.6 Special precautions for disposal

No special requirements.

7. APPLICANT/MANUFACTURER/MANUFACTURER:

TUYIL PHARMACEUTICAL INDUSTRIES LIMITED

NO 22, NEW YIDI ROAD ILORIN, KWARA STATE NIGERIA